Merck & Co and AbbVie co-led the biotech company's funding round, which included Mayo Clinic, Alexandria Venture Investments and Amgen.

MRL Ventures and AbbVie Ventures, the respective corporate venturing units of pharmaceutical firms Merck & Co and AbbVie, co-led a $23m series A round for US-based biotech company Rheostat Therapeutics yesterday.

The round featured Amgen Ventures, the corporate venturing arm of pharmaceutical company Amgen, Alexandria Venture Investments, the strategic investment division of life sciences real estate investment trust Alexandria Real Estate Equities, and medical research group Mayo Clinic.

Venture capital firm SV Health Partners and Dementia Discovery Fund (DDF), a…